Cara Therapeutics (CARA)

Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company developing novel products to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate is intravenous CR845, which has completed phase 2 clinical trials for the treatment acute postoperative pain and is in phase 2 for the treatment of uremic pruritus (itching in dialysis patients). The company is also developing an oral version of CR845 that has completed phase 1 clinical trial for the treatment of moderate-to-severe acute and chronic pain.